Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

What oncology patients say about pathology reports

March 2025—A study of oncology patients at the Medical College of Wisconsin sheds light on how they perceive the content and timing of pathology report review. The study findings were gathered through in-person and telehealth interviews with patients with breast, endocrine, gastrointestinal, genitourinary, and thoracic malignancies. Medical student Amber Y. Bo, MD, in 2022 and 2023 conducted 230 interviews with patients who had a prior opportunity to review their reports in the patient portal.

Changes to note in all common, lab general checklists

March 2025—Revised requirements in the 2024 edition of the CAP accreditation all common and laboratory general checklists address the activity menu, alternative performance assessment, the quality management system, and infectious disease reporting, among other things. “When we make revisions in the requirements, we do it for good reason,” says Stephen J. Sarewitz, MD, advisor to and immediate past chair of the CAP Checklists Committee. “In many cases it is to clarify something that was unclear” and raised questions. “In other cases, a change addresses an area in which laboratories get deficiencies, which we are trying to prevent. We also want to reflect state-of-the-art laboratory medicine. As it advances, the checklists are revised accordingly.”

On value, preanalytics, and personnel in urinalysis

March 2025—Urinalysis reflex rules, reimbursement, instruments, research, and specimen handling and transport are some of what came up in the Jan. 15 roundtable with eight participants online and CAP TODAY publisher Bob McGonnagle leading the discussion.

From the President’s Desk

March 2025—The number of payment and coverage challenges coming from private payers and being experienced by pathologists, our clinical labs, and our patients has exploded in recent years. The CAP has been tracking this increase closely and the problem seems to be getting worse by the month.

Clinical pathology selected abstracts

March 2025—Generative artificial intelligence is now readily available and has created a plethora of interest in health care, including in pathology and laboratory medicine. Unlike traditional AI, generative AI (Gen­AI) doesn’t rely solely on historical data to make predictions but instead uses patterns within historical data to create entirely new data. Excitement over Gen­AI must be weighed against the reality of maintaining human control over the technology and interpreting the data. The use of Gen­AI in health care may include not only streamlining administrative tasks but also performing safety critical clinical functions, such as image-based diagnosis. The risk-based approach and quality management of Gen­AI must be managed individually for each situation.

Anatomic pathology selected abstracts

March 2025—Invasive lobular carcinoma is characterized by loss of E-cadherin expression and CDH1 gene inactivation. The reliability and reproducibility of diagnosis for this tumor type is suboptimal and could be improved by better understanding the histomolecular and clinical heterogeneity of such tumors. The authors analyzed the relationship between the presence, type, or position of CDH1 mutations, E-cadherin expression, and clinicopathological features, including outcome, in a retrospective series of 251 primary invasive lobular carcinomas (ILC) with a median follow-up of 9.5 years. The mutational status of CDH1 (the gene encoding E-cadherin) was determined by RNA sequencing of frozen tumor samples. E-cadherin immunohistochemistry was performed with antibodies directed against the intracellular (clone 4A2C7) and extracellular (clone NCH38) domains.

Molecular pathology selected abstracts

March 2025—Genomic imprinting is an epigenetic process that results in expression of only one copy of a gene—either from a person’s mother or father—while the other parent’s copy of the same gene is silenced. A cluster of genes affected by imprinting on the proximal part of the long arm of chromosome 15 (15q11-q13) are associated with syndromic conditions. Deficient expression of the maternally inherited copy of UBE3A in this region results in Angelman syndrome, which is characterized by severe developmental delay, gait ataxia, and an apparent happy demeanor with profuse smiling, frequent laughing, and excitability. In contrast, deficient expression of paternally inherited genes in this region causes Prader-Willi syndrome. Clinical features of this condition can vary but often include developmental delay, short stature, hyperphagia, and obesity.

Newsbytes

March 2025—Delays while a courier is sent to the blood bank. Errors in judgment. Omission of steps in tracking who received a unit of blood. Wastage of blood product because clinicians were cautious and overordered or ordered too soon. Staffing issues. All of these potential blood bank-related problems can be mitigated with smart blood-storage devices, also called smart refrigerators or blood vending machines.

Q&A column

March 2025
Q. When should plasma mixing tests be performed in the coagulation laboratory, and how are they best interpreted? Read answer.

Q. How important is it for a laboratory to perform whole mount specimen collection and examination? Read answer.

Put It on the Board

March 2025—The Roche Tina-quant Lipoprotein (a) Gen.2 Molarity assay received 510(k) clearance from the Food and Drug Administration. It is the first 510(k)-cleared test of its kind available in the U.S. to measure lipoprotein(a) in nanomoles per liter. It will be broadly available on Cobas c analyzers. Lp(a) can vary in size and has no single, defined molecular weight. For this reason, Roche says, there is a consensus in the scientific community that Lp(a) levels should be measured in terms of the number of particles per liter of blood (nmol/L), rather than mass units (mg/dL), and that any conversion between mass and molar units is generally imprecise and unreliable. By using molar units, laboratory professionals and clinicians know the Lp(a) measurements reflect the number of particles rather than a difference in particle size.

MARKETPLACE

TRENDING